WEGOVY APPROVED for heart disease and stroke risk reduction

 The maker of Ozempic and Wegovy has received government approval to sell its products to reduce the risk of heart attack,

  heart disease, and stroke, which might increase insurance coverage for the popular treatments.

The FDA revealed in a press release that Novo Nordisk, the Danish firm behind the insanely popular weight

  loss injectables, has received the first heart health approval for overweight or obese adults.

 Wegovy is the first weight loss medicine licensed to prevent life-threatening cardiovascular events in individuals with cardiovascular disease and obesity or overweight,"

 This patient group has an increased risk of heart attack, stroke, and cardiovascular death. Providing a proven cardiovascular risk-lowering therapy is a big public health breakthrough."

 Novo reported last August that semaglutide, the active ingredient in Wegovy and Ozempic, improved heart health in a big human experiment.

 Wegovy's 2.4-milligram dosage reduced heart disease risk compared to Ozempic's 1 mg.

For more

Reminders For Each Zodiac Sign When Life Feels Like It’s Falling Apart